生物科技案例研究

過濾

Reset filter
2023/9/26 Case Study

Rapid Subject Enrollment achieved for a Global COVID-19 Vaccine Study for an international…

Background  In 2021, as the world grappled with the COVID-19 pandemic, there emerged an urgent imperative for the development a

了解更多
2019/8/28 Case Study

Phase I study helps company secure second indication for lead product with Healthy volunteer study…

The Background  Early clinical-stage US biotech DiaMedica engaged Novotech to provide CRO services and help it take advantage o

了解更多
2019/8/27 Case Study

尋找腫瘤學 CRO 服務的生物科技公司。法規與招募上的專業知識加快了腫瘤臨床試驗的時間表。

背景介紹 當南韓腫瘤生物科技公司 PharmAbcine 在國內成功完成了治療轉移性/頑固性實質固態瘤的第 I 期試驗時，他們渴望進展到第 II 期。

了解更多
2019/8/27 Case Study

Clinical trial monitoring supports phase III wet AMD trial

When a global pharmaceutical company and its CRO partner required assistance recruiting for a phase III trial investigating a wet AMD pro

了解更多
2019/8/26 Case Study

Biotechnology company looking for Cardiovascular CRO services. Trial monitoring helps change…

The Background As part of a global registry study, the Thrombosis Research Institute (TRI) engaged Novotech to monitor a regist

了解更多
2019/8/25 Case Study

挽救試驗和腫瘤學 CRO 服務當地技術使關鍵的乳癌試驗重回正軌

背景介紹 當一項全球乳癌試驗的招募工作正面臨延滯時，Novotech 被聘為亞太地區 CRO，以幫助該專案重回正軌。

了解更多
2019/8/23 Case Study

Providing Dermatology CRO services. Helping an acne trial overcome recruitment challenges

The Background  Early clinical-stage US dermatology biotech Botanix Pharmaceuticals  was keen to accelerate the clinical develo

了解更多
2019/8/23 Case Study

提供感染性疾病 CRO 服務為全球第 III 期肺病試驗，在亞太區進行關鍵招募。

背景介紹 作為其全球第 III 期試驗的一部分，一家美國生物科技公司要求納入特定的亞太區國家，因為這些國家中鳥型分枝桿菌 (MAC) 的盛行率很高。

了解更多
2019/8/21 Case Study

Providing Gastrointestinal CRO services and Metabolic diseases CRO services. Integrated approach…

The Background Novotech was engaged as a full-service CRO in a multicenter phase I/II obesity treatment research program.

了解更多
2019/8/20 Case Study

提供感染性疾病 CRO 服務咽炎試驗在有限的冬季時間窗口達成目標

背景介紹 延遲試驗開始，意味著 Novotech 面臨著在短短 8 週內要招募 320 名患者的挑戰，而招募情況原本已經有困難了。

了解更多